+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

  • ID: 5024208
  • Report
  • May 2020
  • Region: Global
  • 99 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

Summary

“Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from the publisher's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope
  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to Buy
  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Note: Product cover images may vary from those shown
2 of 2
1. Table of Contents
List of Tables
List of Figures

2. Deal Values in Pharmaceutical and Healthcare Industry Increased in March2020
2.1. Pharmaceuticals & Healthcare, Deals Summary, March 2020

3. Pharmaceuticals & Healthcare, Global, Deal Summary,
3.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2020
3.2. Pharmaceuticals & Healthcare, Global, Major Deals, March 2020
3.2.1. Thermo Fisher Scientific to Acquire Qiagen
3.2.2. Gilead Sciences Acquires Forty Seven
3.2.3. Silence Therapeutics Enters into Collaboration with Astrazeneca
3.2.4. CytomX Therapeutics Enters into Agreement with Astellas Pharma
3.2.5. Pfizer Raises USD1.25 Billion in Public Offering of 2.625% Notes Due 2030
3.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2020
3.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2020

4. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2020

6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

7. Deal Summary by Geography

8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors

9. Further Information
9.1. Methodology
9.2. About the Publisher
9.3. Contact the Publisher
9.4. Disclosure information
9.5. Disclaimer

List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2020
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2020
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2020
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019- March 2020
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2020
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2020
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2019- March 2020
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2020
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2019- March 2020
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2020
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019- March 2020
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2019- March 2020
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2020
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, October 2019- March 2020
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2020
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2020
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2020
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2020
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2019- March 2020

List of Figures
Figure 1: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, March 2020
Figure 2: Pharmaceuticals & Healthcare, Number of Licensing Deals By Payment Mode, October 2019 - March 2020
Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, March 2020
Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Type, March 2020
Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2020
Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2020
Figure 8: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 9: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019- March 2020
Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 13: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019- March 2020
Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2020
Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2020
Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 17: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019- March 2020
Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019- March 2020
Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2019- March 2020
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2019- March 2020
Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2019- March 2020
Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2020
Figure 31: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 38: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 39: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 40: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 41: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 42: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Figure 43: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2019- March 2020
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll